Drug Farm Presents Positive Ophthalmologic and Systemic Findings from International Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at APVRS 2026

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--Drug Farm today announced positive ophthalmologic and systemic findings from its international Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, presented at the Asia-Pacific Vitreo-retina Society (APVRS) 2026 Congress in Gold Coast, Australia. The presentation highlighted early evidence of improvements across multiple major manifestations of ROSAH syndrome, including visual function, anhidrosis, headache, arthralgia, quality of life, and